Magenta Therapeutics, a clinical-stage biotechnology company, announced that the company presented Phase 2 clinical data on its cell therapy, MGTA-456, at the annual meeting of the American Academy of Neurology in Philadelphia, Pennsylvania.
MGTA-456 is a cell therapy designed to provide a high dose of hematopoietic stem cells that are well-matched to the patient. The Company plans to enroll 12 patients in the ongoing Phase 2 study in inherited metabolic disorders, which include cALD, Hurler syndrome, metachromatic leukodystrophy and globoid cell leukodystrophy.
The primary endpoint of the study is neutrophil engraftment after transplantation. The study is also collecting both short- and long-term disease-specific outcomes. Data from the first five evaluable patients treated in this study were highlighted in a poster presented by Ashish Gupta, MBBS, M.P.H., Assistant Professor, Department of Pediatrics and Division of Blood and Marrow Transplantation, University of Minnesota.
In a separate oral presentation today, Kevin Goncalves, Ph.D., Magenta Therapeutics, will highlight preclinical data demonstrating that the high stem cell dose in MGTA-456 accelerates and improves engraftment of human microglia in the brains of transplanted mice.
“We are very pleased to see signs of durable disease benefit in patients with cALD,” said John Davis, M.D., M.P.H., Chief Medical Officer, Magenta Therapeutics. “cALD is a rapidly progressive disease, and patients whose disease progresses quickly typically have poor long-term outcomes. The stable neurological function score and persistent decrease in brain inflammation in these two patients suggest that we have halted the inflammatory process associated with the disease which may provide long-term benefits. We look forward to providing an additional update from the study before the end of the year.”
Patients with Inherited Metabolic Disorders (IMDs) transplanted with MGTA-456, a CD34+ Expanded Cell Therapy Product, Show Rapid Engraftment in Preliminary Phase 2 Trial Results.